CODX — Co-Diagnostics Balance Sheet
0.000.00%
- $18.54m
- $10.31m
- $0.62m
Annual balance sheet for Co-Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 89.9 | 81.3 | 58.5 | 29.7 | 11.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 20.9 | 5.4 | 0.331 | 0.133 | 0.235 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 115 | 92.7 | 62.1 | 32.3 | 13.7 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.93 | 2.91 | 6 | 4.88 | 3.48 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 160 | 123 | 95.3 | 63.6 | 24.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 12.6 | 3.87 | 5.75 | 7.32 | 3.54 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 25.6 | 8.57 | 9.31 | 9.69 | 4.11 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 134 | 115 | 86 | 53.9 | 20.6 |
| Total Liabilities & Shareholders' Equity | 160 | 123 | 95.3 | 63.6 | 24.7 |
| Total Common Shares Outstanding |